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Abstract
Background: The mitochondrial DNA (mtDNA) T16189C polymorphism, with a homopolymeric
C-tract of 10–12 cytosines, is a putative genetic risk factor for idiopathic dilated cardiomyopathy
in the African and British populations. We hypothesized that this variant may predispose to dilated
cardiomyopathy in people who are infected with the human immunodeficiency virus (HIV).
Methods: A case-control study of 30 HIV-positive cases with dilated cardiomyopathy and 37 HIV-
positive controls without dilated cardiomyopathy was conducted. The study was confined to
persons of black African ancestry to minimize confounding of results by population admixture. HIV-
positive patients with an echocardiographically confirmed diagnosis of dilated cardiomyopathy and
HIV-positive controls with echocardiographically normal hearts were studied. Patients with
secondary causes of cardiomyopathy (such as hypertension, diabetes, pregnancy, alcoholism,
valvular heart disease, and opportunistic infection) were excluded from the study. DNA samples
were sequenced for the mtDNA T16189C polymorphism with a homopolymeric C-tract in the
forward and reverse directions on an ABI3100 sequencer.
Results: The cases and controls were well matched for age (median 35 years versus 34 years, P =
0.93), gender (males 60% vs 53%, P = 0.54), and stage of HIV disease (mean CD4 T cell count 260.7/
μL vs. 176/μL, P = 0.21). The mtDNA T16189C variant with a homopolymeric C-tract was
detected at a frequency of 26.7% (8/30) in the HIV-associated cardiomyopathy cases and 13.5% (5/
37) in the HIV-positive controls. There was no significant difference between cases and controls
(Odds Ratio 2.33, 95% Confidence Interval 0.67–8.06, p = 0.11).
Conclusion: The mtDNA T16189C variant with a homopolymeric C-tract is not associated with
dilated cardiomyopathy in black African people infected with HIV.
Published: 27 April 2009
BMC Medical Genetics 2009, 10:37 doi:10.1186/1471-2350-10-37
Received: 28 October 2008
Accepted: 27 April 2009
This article is available from: http://www.biomedcentral.com/1471-2350/10/37
© 2009 Shaboodien et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2009, 10:37 http://www.biomedcentral.com/1471-2350/10/37
Page 2 of 5
(page number not for citation purposes)
Background
It is well-established that a proportion of patients who are
infected with the human immunodeficiency virus (HIV)
develop cardiomyopathy during the natural history of the
retroviral disease [1]. A recent study from Rwanda has
shown that the prevalence of HIV-associated cardiomyop-
athy is 17.7% in an African outpatient population, with
low socio-economic status, longer duration of HIV infec-
tion, advanced HIV disease, and low plasma selenium lev-
els being the main predisposing factors [2]. It is not
known, however, whether genetic factors play any role in
the predisposition to dilated cardiomyopathy in people
who are infected with HIV [3].
A major advance in the study of the pathogenesis of idio-
pathic dilated cardiomyopathy has been the demonstra-
tion that 20–30% of cases are familial, suggesting that
genetic factors may be involved in the aetiology of the dis-
ease [4]. In cases of sporadic dilated cardiomyopathy,
genetic factors might confer increased susceptibility to dis-
ease in association with other environmental factors such
as viral myocarditis. In addition to nuclear DNA abnor-
malities, mutations in the mitochondrial DNA (mtDNA)
are known to contribute to the development of cardiomy-
opathy [5]. The myocardium is dependent on mitochon-
dria for cellular oxidative phosphorylation and is,
therefore, susceptible to genetic defects that affect mito-
chondrial function.
The importance of genetic risk factors is underscored by
the reported association between the mtDNA T16189C
variant with a homopolymeric C-tract in African and Brit-
ish populations [6]. Nucleotide T16189 lies in the middle
of a homopolymeric-C tract where the transition from a
thymine (T) to a cytosine (C) causes a homopolymeric C-
tract of 10–12 bp in the displacement loop (D-loop)
region of the mtDNA.
As expected, the association data of Khogali et al imply
that the variant increases susceptibility to idiopathic
dilated cardiomyopathy, but the presence of the variant is
not sufficient to cause disease. The mtDNA T16189C var-
iant maps precisely to a novel point of origin of mtDNA
replication (OriB), which makes it likely that the variant
will alter mitochondrial DNA function [7]. Therefore, the
critical position of the T16189C variant in the mitochon-
drial genome suggests that the variant might have a direct
role in the pathogenesis of dilated cardiomyopathy.
Indeed, the T16189C variant with a 10–12 base pair
homopolymeric C tract appears to be a genetic risk factor
for other disorders, such as diabetes mellitus [8], and low
birth weight [9]and is thus of medical interest.
A proportion of cases of idiopathic dilated cardiomyopa-
thy is thought to be due to previous viral myocarditis [10].
We postulated that the mtDNA T16189C variant might
predispose to dilated cardiomyopathy in people with a
virus-associated form of cardiomyopathy, such as HIV-
associated cardiomyopathy. We tested this hypothesis in a
case-control study.
Methods
Study design
This was a case-control study of 30 cases of HIV-associated
cardiomyopathy and 37 HIV-positive patients with
echocardiographically normal hearts. Spurious associa-
tions may arise in genetic association studies due to the
inclusion of a population sub-group having different
allele frequencies for the variant under study [11]. To con-
trol for this source of confounding, the cases and controls
were drawn from people of black African ancestry. The
study was approved by the Research Ethics Committee of
the University of Cape Town, and all participants gave
written informed consent.
A commercial kit (Qiagen, DNA blood minikit, Southern
Cross, USA) was used to isolate total DNA from blood
samples according to standard methods. The DNA was
analysed for the mtDNA T16189C variant with a
homopolymeric C-tract using standard PCR and sequenc-
ing of the D-loop region (nucleotides 15894–16401) in
both the forward and reverse directions [6]. The resultant
amplicon was sequenced on the ABI3100 and analysed.
Statistics
Logistic regression models were fitted to assess the associ-
ation between HIV-associated cardiomyopathy and the
mtDNA T16189C variant with a homopolymeric C-tract;
a p-value of <0.05 was considered significant. Based on
the realised number of cases and controls, the statistical
power of the study was 80% (β = 0.20) based on a 90%
level of significance (α = 0.10).
Results
The clinical characteristics of the cases and controls are
summarised in Table 1. We enrolled 30 cases of HIV-asso-
ciated cardiomyopathy. Thirty seven HIV-positive con-
trols with normal echocardiography examination were
identified. The cases and controls were well matched for
age, gender, and stage of HIV disease as determined by
CD4 T cell count and HIV viral load (Table 1).
We found the mtDNA T16189C variant with a homopol-
ymeric C-tract occurred at a frequency of 26.7% (8/30) in
the HIV-associated cardiomyopathy cases and in 13.5%
(5/37) of the HIV-positive controls with no cardiomyop-
athy (Table 2). When analyzing the T16189C transition
alone, without regard to the presence or absence of an
uninterrupted C-tract, we found the variant to occur at a
frequency of 70% (21/30) in the HIV-associated cardio-BMC Medical Genetics 2009, 10:37 http://www.biomedcentral.com/1471-2350/10/37
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myopathy cases and 62.2% (23/37) of the HIV-positive
controls with no cardiomyopathy.
There was no significant statistical association (Figure 1)
between the mtDNA T16189C variant with a homopoly-
meric C-tract (Odds ratio 2.33, 95% Confidence interval
0.67 – 8.06) or the T16189C variant alone (Odds ratio
1.42, 95% Confidence interval 0.45 – 4.49) with HIV-
associated cardiomyopathy (Table 2).
Discussion
To the best of our knowledge, this is the first study of
genetic risk factors in HIV-associated cardiomyopathy.
This study found no significant association between the
mtDNA T16189C variant with a homopolymeric C-tract
and HIV-associated cardiomyopathy. However, there are
differences between this study and the original report that
found an association between the mtDNA T16189C vari-
ant with a homopolymeric C-tract and dilated cardiomy-
opathy [6]. Khogali et al studied patients with idiopathic
dilated cardiomyopathy who were not tested for HIV,
whereas we studied cases of HIV-associated cardiomyopa-
thy and HIV infected controls. It is likely that some cases
of idiopathic dilated cardiomyopathy result from unrec-
ognized viral myocarditis early in life, a factor that led us
to postulate that the same variant may predispose to an
inflammatory cardiomyopathy such as HIV-associated
cardiomyopathy. Idiopathic dilated cardiomyopathy is
likely to represent a more heterogeneous group than
patients with HIV-associated cardiomyopathy.
In the Khogali study, the finding of an association
between the mtDNA T16189C variant containing a
homopolymeric C-tract with idiopathic dilated cardiomy-
opathy in black Africans was based on 22 cases and 19
controls, a sample size that is smaller than the present
study. It is well recognised that small gene association
studies may be associated with false-positive findings
[12]. The putative genetic association of the ACE I/D pol-
ymorphism with myocardial infarction is a salutary case
in this regard. A series of smaller studies showed extreme,
albeit conflicting findings of an association between ACE
I/D genotype and myocardial infarction [13]. A larger,
and adequately powered validation study was required to
produce a more realistic estimate of the effect of the ACE
I/D polymorphism on the risk of myocardial infarction;
indeed a study involving thousands of cases and thou-
sands of control showed no significant association
between the ACE I/D polymorphism and the risk of myo-
cardial infarction [13].
Table 1: Clinical characteristics of the HIV-associated cardiomyopathy cases and HIV-positive controls
HIVAC HIV positive controls P value
Median Age (IQR, ± Stdev) 35 (27–41, ± 9.3) 34 (30–38, ± 7.7) 0.93
Gender
Male 18 (60%) 20 (52.6%) 0.54*
female 12 (40%) 17 (45.9%)
Mean LVEF (± Stdev) 33.4 (± 11.8) 66.7 (± 11.3) 0.0001
Mean LVIDd (± Stdev) 5.9 (± 0.88) 4.4 (± 0.50) 0.0001
Mean CD4 count (± Stdev) 260.7 (± 213.8) 176.1 (± 152.7) 0.21
RNA viral load (median) 680,774.2 (92,000) 231,574.8 (66,000) 0.16
Number 30 37
HIVAC, HIV-associated cardiomyopathy; IQR, inter-quartile range; Stdev, standard deviation; * Mann-Whitney non-parametric test; LVIDd: left 
ventricular internal dimension in diastole
Table 2: Frequency of other polymorphisms in the 10 bp D-loop region (16184 bp–16193 bp) in cases and controls
16184 bp – 16193 bp HIVAC (%) HIV+ (%) X2 P value OR
Wild Type CCCCCTCCCCC
T16189C - - - - - C - - - - 21 (70) 23 (62.2) 0.44 0.50 1.42 (0.45–4.49)
Homopolymeric length variants 8 (30) 5 (13.5) 1.81 0.18 2.33 (0.67–8.06)
(a) length variant C -10 AAAA CCCCCCCCCC 7 (23) 3 (8) 2.98 0.08 3.45 (0.68–22.40)
(b) length variant C -11 AAAC CCCCCCCCCC 1 (3) 1 (2.7) 0.33 1.0 1.24 (0.02–100.11)
(c) length variant C -12 AACC CCCCCCCCCC 0 1 (2.7) 0.01 1.0 0.0 (0.0–48.10)
Cohort Total 30 37
bp, base-pairs; %, Percentage; X2, chi square; OR, odds ratioBMC Medical Genetics 2009, 10:37 http://www.biomedcentral.com/1471-2350/10/37
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In the present study, it is uncertain whether the lack of sig-
nificant difference between the cases and controls is
related to a real absence of an association between the
mtDNA T16189C variant with a homopolymeric C-tract
and HIV-associated cardiomyopathy (i.e true-negative)
or, due to inadequate statistical power of the present study
(i.e false-negative). It is of interest that the original study
of Khogali et al has not been replicated by other research-
ers, which suggests that the putative association of the
mitochondrial T16189C with dilated cardiomyopathy
requires independent validation. Other studies investigat-
ing this question have only addressed the frequency of the
T16189C single nucleotide polymorphism and not the
accompanying homopolymeric tract [14].
Conclusion
We found that the mitochondrial T16189C variant with a
homopolymeric-C tract was not associated with an
increased risk of HIV-associated cardiomyopathy. Our
finding therefore, raises concern about the validity of the
putative association between the T16189C variant and
cardiomyopathy in the original small study by Khogali
[6]. One way of resolving this uncertainty is to conduct a
validation study in an adequately powered study of cases
and controls with dilated cardiomyopathy, and to pool
the findings with all relevant studies in a meta-analysis
[15].
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Forest plot indicating the frequency of the mtDNA T16189C variant with a homopolymeric C-tract in HIV-associated cardio- myopathy patients and HIV-positive controls Figure 1
Forest plot indicating the frequency of the mtDNA T16189C variant with a homopolymeric C-tract in HIV-
associated cardiomyopathy patients and HIV-positive controls.
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